Researchers uncover insights into pioneer transcription factors 25 January 2021 | By Victoria Rees (Drug Target Review) A research team has discovered how proteins called pioneer transcription factors turn on vital genes in cells.
SARS-CoV-2 triggers antibodies from previous coronavirus infections 22 January 2021 | By Victoria Rees (Drug Target Review) A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
Could synNotch CAR T cells be the answer to fighting solid tumours? 22 January 2021 | By Hannah Balfour (Drug Target Review) Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.
Study defines small-cell lung cancer subtypes and therapeutic vulnerabilities 22 January 2021 | By Victoria Rees (Drug Target Review) Researchers have identified four unique subtypes of small-cell lung cancer (SCLC) following the characterisation of cell types.
T-cell exhaustion may limit long-term immunity in COVID-19 patients 22 January 2021 | By Hannah Balfour (Drug Target Review) Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
Scientists develop potential ‘smart’ stem cells made from human fat 21 January 2021 | By Victoria Rees (Drug Target Review) Using a new compound mixture, researchers have created adaptive and regenerative stem cells from human fat cells.
Novel target could improve the efficacy of treatments for renal cell carcinoma 21 January 2021 | By Hannah Balfour (Drug Target Review) A new study shows that upregulating the activity of the ACE2 signalling pathway in kidney cancer cells enhances the effects of clinically used treatments.
Targeting PEG2 reverses age-related cognitive decline in mice 21 January 2021 | By Hannah Balfour (Drug Target Review) The discovery of an inflammatory pathway promoting brain ageing and cognitive decline could lead to new treatments for age-related conditions.
Novel IRF4 inhibitor shows promise as myeloma treatment in mice 21 January 2021 | By Victoria Rees (Drug Target Review) An antisense oligonucleotide has been developed by researchers to inhibit IRF4 as a potential strategy to treat multiple myeloma.
Discovering the mechanisms of antibiotic resistance could lead to better drugs 20 January 2021 | By Hannah Balfour (Drug Target Review) A single change to the structure of bacterial ribosomes prevents macrolide antibiotics from binding and killing the bacteria, according to a study.
Severe symptoms of COVID-19 are caused by brain infection in mice, finds study 20 January 2021 | By Hannah Balfour (Drug Target Review) Researchers found that SARS-CoV-2 persists in the brain after it is cleared in the lungs and concluded the severest and longest lasting symptoms of COVID-19 may be caused by brain infection.
CBD shown to kill Gram-negative bacteria in pre-clinical studies 20 January 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that CBD can kill Gram-negative bacteria, which could lead to the first new class of antibiotics for resistant bacteria in 60 years.
Researchers discover mechanism behind severe cases of G6PD deficiency 20 January 2021 | By Victoria Rees (Drug Target Review) Researchers have revealed how the most severe cases of G6PD deficiency occur, which could help scientists design new drugs for the disease.
Scientists identify nutrient that helps prevent bacterial infection 19 January 2021 | By Victoria Rees (Drug Target Review) Scientists have identified a potential alternative to antibiotics, a nutrient named taurine that helps the microbiome kill invading bacteria.
New tissue engineering process brings laboratory-grown organs one step closer 19 January 2021 | By Hannah Balfour (Drug Target Review) Researchers have developed a new technique that that could one day enable us to grow fully functional human organs in the laboratory.
